Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

30 Sep 2020 14:27

RNS Number : 6378A
Motif Bio PLC
30 September 2020
 

 

 

Motif Bio plc

 

("Motif Bio" or the "Company")

 

Result of AGM

 

Motif Bio plc (AIM: MTFB) announces that at the Annual General Meeting of the Company held earlier today at the offices of ONE Advisory Limited, 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT all but one of the resolutions put to members were passed on a poll.

 

The Board notes that resolution 7, which was proposed as a special resolution regarding the disapplication of pre-emption rights, was not passed.

 

The number of votes lodged by proxy and voted on by poll for and against each of the resolutions proposed, and the number of votes withheld, were as follows:

 

Resolution

FOR*

%

AGAINST

%

WITHHELD

Resolution 1 (Ordinary)

To receive the Company's annual accounts and the strategic, directors' and auditors' reports for the year ended 31 December 2019.

 

37,371,686

 

91.94

 

 

3,275,355

 

8.06

 

 

131,590

Resolution 2 (Ordinary)

To re-elect Graham Lumsden as a Director of the Company

 

27, 167,596

 

66.74

 

 

13,541,866

 

33.26

 

 

69,169

Resolution 3 (Ordinary)

To re-elect Christopher Wardhaugh as a director of the Company, who was appointed by the board since the last annual general meeting.

 

 

34,740,854

 

 

85.42

 

 

 

5,930,684

 

 

14.58

 

 

 

107,093

Resolution 4 (Ordinary)

To re-appoint the Company's auditor Crowe LLP, who have been appointed by the board since the last annual general meeting.

 

 

37,286,396

 

 

91.56

 

 

 

 

3,437,066

 

 

8.44

 

 

 

55,169

Resolution 5 (Ordinary)

That the Directors be authorised to fix the auditors remuneration.

 

36,844,682

 

 

90.71

 

 

 

3,772,431

 

9.29

 

 

161,518

Resolution 6 (Ordinary)

To empower the directors to allot relevant securities pursuant to Section 551 of the Act

 

33,534,192

 

84.95

 

 

5,941,430

 

 

15.05

 

 

1,303,009

Resolution 7 (Special)

To disapply the pre-emptive rights contained in Section 561 of the Act

 

26,246,162

 

73.09

 

 

 

9,844,855

 

26.91

 

 

4,187,614

 

 

 

*including votes granting discretion to the chair

 

As at 30 September 2020, there were 654,991,023 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

 

+44 (0) 20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0) 20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBXGDCXDXDGGG
Date   Source Headline
8th Jun 20172:32 pmRNSHolding(s) in Company
5th Jun 20176:20 pmRNSPublication of Shareholder Circular
2nd Jun 20174:36 pmRNSResult of Placing
2nd Jun 20177:00 amRNSProposed Placing
23rd May 20174:40 pmRNSSecond Price Monitoring Extn
23rd May 20174:35 pmRNSPrice Monitoring Extension
18th May 20177:00 amRNSPublication of UK Annual Report and Accounts
10th May 20177:00 amRNSAppointments to Scientific Advisory Board
5th May 20177:00 amRNSDirectorate Change
2nd May 20173:10 pmRNSExercise of Warrants and Issue of Equity
2nd May 20177:00 amRNSAnnual Financial Report
28th Apr 201712:00 pmRNSChange of Adviser
24th Apr 20177:00 amRNSNotification of change in holding of shareholder
18th Apr 20177:00 amRNSPositive Data Readout for Iclaprim Phase 3 Trial
12th Apr 20173:06 pmRNSHolding(s) in Company
12th Apr 20173:01 pmRNSHolding(s) in Company
31st Mar 20174:15 pmRNSChange of Registered Office
8th Feb 20172:57 pmRNSInvestor Presentation
8th Feb 20177:00 amRNSDirector/PDMR Shareholding
7th Feb 20177:02 amRNSDirector/PDMR Shareholding
31st Jan 20173:36 pmRNSHardman Research: Further de-risking of iclaprim
31st Jan 20177:00 amRNSClinical trial finishes patient treatment phase
27th Jan 20176:13 pmRNSHolding(s) in Company
18th Jan 20177:05 amRNSDirector/PDMR Shareholding
18th Jan 20177:00 amRNSAppointment of Chief Financial Officer
9th Jan 20175:28 pmRNSIssue of Equity
3rd Jan 201712:31 pmRNSHolding(s) in Company
30th Dec 20163:09 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
21st Dec 20165:50 pmRNSConversion of CPNs, PDMR Dealing & TVR
21st Dec 20164:17 pmRNSIssue of Equity & Total Voting Rights
21st Dec 20163:05 pmRNSResult of GM
19th Dec 20165:58 pmRNSHolding(s) in Company
8th Dec 20167:45 amRNSHolding(s) in Company
5th Dec 20167:00 amRNSPublication of circular and notice of GM
1st Dec 20165:27 pmRNSIssue of Equity
25th Nov 201611:32 amRNSHolding(s) in Company
24th Nov 20161:36 pmRNSHolding(s) in Company
23rd Nov 20165:12 pmRNSHolding(s) in Company
23rd Nov 20164:56 pmRNSClosing of public offer
18th Nov 201612:51 pmRNSConfirms successful European placing
18th Nov 20167:16 amRNSUS Pricing and European Placing to raise US$25m
4th Nov 20161:34 pmRNSHolding(s) in Company
4th Nov 20161:20 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSUpdate on US Public Offering
31st Oct 20167:00 amRNSData Confirming Standard Clinical Trial Dosage
31st Oct 20167:00 amRNSNew Data on Iclaprim
16th Sep 20164:40 pmRNSSecond Price Monitoring Extn
16th Sep 20164:35 pmRNSPrice Monitoring Extension
15th Sep 20167:00 amRNSPosters presented at IDWeek New Orleans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.